Clinical Trials
55 trialsNCT06318871 2026-05-11
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
Dana-Farber Cancer Institute
Phase EARLY_PHASE1 Active not recruiting
NCT02964078 2026-04-02
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT02306954 2025-03-10
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
Phase 2 Active not recruiting
NCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT02926053 2024-11-22
TIL Therapy for Metastatic Renal Cell Carcinoma
Herlev Hospital
Phase 1 Completed
NCT04551885 2023-09-21
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT03501381 2023-09-01
High Dose IL 2 and Entinostat in RCC
Hoosier Cancer Research Network
Phase 2 Active not recruiting
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT03970382 2022-08-18
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
Phase 1 Suspended
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT01896271 2021-08-23
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02989714 2021-07-13
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT00083941 2020-10-19
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
Oxford BioMedica
Phase 2 Completed
NCT00325507 2020-10-19
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
Oxford BioMedica
Phase 2 Completed
NCT01355562 2020-04-30
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Loma Linda University
Phase 2 Withdrawn
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT00582790 2019-11-25
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT03111901 2019-07-12
UVA-AM-002
University of Virginia
Phase 1/2 Withdrawn
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02863913 2019-03-06
PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
Peking University
Phase 1 Withdrawn
NCT02867332 2019-03-06
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Peking University
Phase 1 Withdrawn
NCT02867345 2019-03-06
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Peking University
Withdrawn
NCT03226236 2018-11-13
RENALVax-2
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Withdrawn
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT01702909 2018-02-08
Interleukin-2 in Metastatic Kidney Cancer
Western Regional Medical Center
Phase 2 Terminated
NCT02280811 2017-09-06
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00089778 2017-08-01
Vaccine Treatment of Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00003126 2017-01-04
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
Loyola University
Phase 3 Completed
NCT00440973 2016-03-17
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00913913 2015-12-01
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT01160445 2015-10-28
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01273181 2015-10-28
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00276835 2015-04-10
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT01274273 2014-12-02
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
University of Aarhus
Phase 2 Unknown
NCT00004050 2014-07-29
Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer
Vical
Phase 2 Terminated
NCT00005072 2014-07-29
Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer
Vical
Phase 1/2 Terminated
NCT00203866 2013-09-05
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
University of Chicago
Phase 2 Terminated
NCT00100906 2013-08-16
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00502034 2013-07-10
Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3 Completed
NCT00278369 2013-05-22
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00032188 2013-01-24
Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00328861 2012-11-05
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00091611 2012-10-26
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00031564 2012-09-27
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00485563 2012-03-08
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Endocyte
Phase 2 Terminated
NCT00277017 2011-09-27
Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 1/2 Completed
NCT00393029 2011-08-15
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 2 Completed